| Name | Title | Contact Details |
|---|---|---|
Sue H |
Chief People & Administrative Officer | Profile |
Monique McGlinch |
Vice President, Customer Engagement | Profile |
Mark Greenwood |
Vice President, Imaging Product Development | Profile |
Sue Hulsmeyer |
Senior Director -Human Resources | Profile |
Sue Hulsmeyer |
Vice President of Human Resources and Corporate Communications | Profile |
The Curry Rockefeller Group is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Angel Medical Systems is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Angel Medical Systems is based in Shrewsbury, NJ. You can find more information on Angel Medical Systems at www.angel-med.com
Medavie EMS is a health care delivery and management company based in Dartmouth, Nova Scotia, Canada. We have a team of management staff that specializes in the areas of project management, planning, education, human resources, communications finance, physical resources, process design, facilitation, reporting, and information technology. Currently, Medavie EMS is responsible to deliver EMS in Nova Scotia, New Brunswick, Prince Edward Island, the District Municipality of Muskoka in Ontario, the Municipality of Chatham-Kent in Ontario, Elgin County in Ontario, Saskatoon and surrounding areas in Saskatchewan, as well as, communities across eastern Alberta. Each of these systems is managed by subsidiary companies which have established contracts with governments (provincial and municipal) or health authorities. In addition, Medavie EMS operates a patient transfer service in Massachusetts headquartered in Boston. Combined these companies directly employ or manage a total staff of approximately 3800, 550 of whom are in the US.
The Haven Asisted Living is a Mechanicsville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.